Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | GRM5 | P41594 | 13/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | CCR1 | P32246 | 1/20 | 0.46 |
| ▸ | CCR5 | P51681 | 1/20 | 0.46 |
| ▸ | CCR8 | P51685 | 1/20 | 0.46 |
| ▸ | METAP1 | P53582 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.46 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3585013 | 1.00 | TP53 (0.55) | TP53GRM5KDM4ETDP1LMNA | |
| SCHEMBL3585009 | 0.81 | TP53 (0.55) | TP53GRM5KDM4ETDP1LMNA | |
| SCHEMBL3582828 | 0.78 | PPARA (0.41) | — | |
| SCHEMBL14350435 | 0.77 | HDAC6 (0.53) | TP53GRM5LMNA | |
| SCHEMBL4702208 | 0.75 | GRM5 (0.58) | TP53GRM5 | |
| SCHEMBL4699251 | 0.75 | GRM5 (0.76) | GRM5 | |
| SCHEMBL27810667 | 0.75 | HDAC6 (0.51) | TP53GRM5 | |
| SCHEMBL3591846 | 0.74 | PPARA (0.42) | GRM5KDM4ETDP1CYP1A2 | |
| SCHEMBL8117268 | 0.73 | MAOA (0.44) | — | |
| SCHEMBL46305 | 0.73 | CCR1 (0.52) | TP53GRM5KDM4ECCR1CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240116975-A1 | ADENOSINE A3 RECEPTOR AGONISTS, PREPARATION METHODS AND USES THEREOF | ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) | 2024-04-11 | — | — | US | disclosed |
| CN-114845778-A | Dihydrocyclopentaisoquinoline sulfonamide derivative compound | UCB生物制药有限责任公司 | 2022-08-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240116975-A1 | ADENOSINE A3 RECEPTOR AGONISTS, PREPARATION METHODS AND USES THEREOF | ADORA3, ADORA2A, ADORA2B | TP53 4505/4885GRM5 580/4885KDM4E 4613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.